NCT01578720

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Treatment of CNV Secondary to Presumed Ocular Histoplasmosis With EYLEA 2.0mg (Intravitreal Aflibercept Injection)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Retina Research Institute, LLC · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of intravitreal injection of aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS).

Conditions

• Choroidal Neovascularization
• Presumed Ocular Histoplasmosis

Interventions

Type	Name	Description
DRUG	EYLEA (Aflibercept) intravitreal injection	Intravitreal Injection once every 8 weeks with 3 initial monthly doses

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-04-01
• Completion: 2015-03-01
• First posted: 2012-04-17
• Last updated: 2018-08-29

Locations

3 sites across 1 country: United States